chr19-13209374-C-A
Position:
Variant summary
Our verdict is Benign. Variant got -10 ACMG points: 1P and 11B. PP2BP4_ModerateBP6BS1BS2
The NM_001127222.2(CACNA1A):c.6464G>T(p.Arg2155Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000684 in 1,389,252 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: 𝑓 0.00022 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000049 ( 1 hom. )
Consequence
CACNA1A
NM_001127222.2 missense
NM_001127222.2 missense
Scores
2
7
10
Clinical Significance
Conservation
PhyloP100: 2.90
Genes affected
CACNA1A (HGNC:1388): (calcium voltage-gated channel subunit alpha1 A) Voltage-dependent calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, and gene expression. Calcium channels are multisubunit complexes composed of alpha-1, beta, alpha-2/delta, and gamma subunits. The channel activity is directed by the pore-forming alpha-1 subunit, whereas, the others act as auxiliary subunits regulating this activity. The distinctive properties of the calcium channel types are related primarily to the expression of a variety of alpha-1 isoforms, alpha-1A, B, C, D, E, and S. This gene encodes the alpha-1A subunit, which is predominantly expressed in neuronal tissue. Mutations in this gene are associated with 2 neurologic disorders, familial hemiplegic migraine and episodic ataxia 2. This gene also exhibits polymorphic variation due to (CAG)n-repeats. Multiple transcript variants encoding different isoforms have been found for this gene. In one set of transcript variants, the (CAG)n-repeats occur in the 3' UTR, and are not associated with any disease. But in another set of variants, an insertion extends the coding region to include the (CAG)n-repeats which encode a polyglutamine tract. Expansion of the (CAG)n-repeats from the normal 4-18 to 21-33 in the coding region is associated with spinocerebellar ataxia 6. [provided by RefSeq, Jul 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -10 ACMG points.
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), CACNA1A. . Gene score misZ 5.7845 (greater than the threshold 3.09). Trascript score misZ 3.9354 (greater than threshold 3.09). GenCC has associacion of gene with benign paroxysmal torticollis of infancy, developmental and epileptic encephalopathy, 42, undetermined early-onset epileptic encephalopathy, episodic ataxia type 2, familial or sporadic hemiplegic migraine, spinocerebellar ataxia type 6, Lennox-Gastaut syndrome, migraine, familial hemiplegic, 1.
BP4
Computational evidence support a benign effect (MetaRNN=0.07586345).
BP6
Variant 19-13209374-C-A is Benign according to our data. Variant chr19-13209374-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 289416.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=3, Uncertain_significance=4}. Variant chr19-13209374-C-A is described in Lovd as [Likely_benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.000223 (34/152280) while in subpopulation AFR AF= 0.000577 (24/41564). AF 95% confidence interval is 0.000398. There are 0 homozygotes in gnomad4. There are 15 alleles in male gnomad4 subpopulation. Median coverage is 33. This position pass quality control queck.
BS2
High AC in GnomAd4 at 34 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CACNA1A | NM_001127222.2 | c.6464G>T | p.Arg2155Leu | missense_variant | 45/47 | ENST00000360228.11 | NP_001120694.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CACNA1A | ENST00000360228.11 | c.6464G>T | p.Arg2155Leu | missense_variant | 45/47 | 1 | NM_001127222.2 | ENSP00000353362.5 | ||
CACNA1A | ENST00000638029.1 | c.6482G>T | p.Arg2161Leu | missense_variant | 46/48 | 5 | ENSP00000489829.1 | |||
CACNA1A | ENST00000573710.7 | c.6470G>T | p.Arg2157Leu | missense_variant | 45/47 | 5 | ENSP00000460092.3 | |||
CACNA1A | ENST00000635727.1 | c.6467G>T | p.Arg2156Leu | missense_variant | 45/47 | 5 | ENSP00000490001.1 | |||
CACNA1A | ENST00000637769.1 | c.6467G>T | p.Arg2156Leu | missense_variant | 45/47 | 1 | ENSP00000489778.1 | |||
CACNA1A | ENST00000636012.1 | c.6431G>T | p.Arg2144Leu | missense_variant | 44/46 | 5 | ENSP00000490223.1 | |||
CACNA1A | ENST00000637736.1 | c.6326G>T | p.Arg2109Leu | missense_variant | 44/46 | 5 | ENSP00000489861.1 | |||
CACNA1A | ENST00000636389.1 | c.6467G>T | p.Arg2156Leu | missense_variant | 45/47 | 5 | ENSP00000489992.1 | |||
CACNA1A | ENST00000637432.1 | c.6482G>T | p.Arg2161Leu | missense_variant | 46/48 | 5 | ENSP00000490617.1 | |||
CACNA1A | ENST00000636549.1 | c.6473G>T | p.Arg2158Leu | missense_variant | 46/48 | 5 | ENSP00000490578.1 | |||
CACNA1A | ENST00000637927.1 | c.6470G>T | p.Arg2157Leu | missense_variant | 45/47 | 5 | ENSP00000489715.1 | |||
CACNA1A | ENST00000635895.1 | c.6467G>T | p.Arg2156Leu | missense_variant | 45/47 | 5 | ENSP00000490323.1 | |||
CACNA1A | ENST00000638009.2 | c.6467G>T | p.Arg2156Leu | missense_variant | 45/47 | 1 | ENSP00000489913.1 | |||
CACNA1A | ENST00000637276.1 | c.6431G>T | p.Arg2144Leu | missense_variant | 44/46 | 5 | ENSP00000489777.1 | |||
CACNA1A | ENST00000636768.1 | n.*730G>T | non_coding_transcript_exon_variant | 9/10 | 5 | ENSP00000490190.2 | ||||
CACNA1A | ENST00000636768.1 | n.*730G>T | 3_prime_UTR_variant | 9/10 | 5 | ENSP00000490190.2 |
Frequencies
GnomAD3 genomes AF: 0.000223 AC: 34AN: 152162Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
34
AN:
152162
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000205 AC: 1AN: 48850Hom.: 0 AF XY: 0.0000404 AC XY: 1AN XY: 24770
GnomAD3 exomes
AF:
AC:
1
AN:
48850
Hom.:
AF XY:
AC XY:
1
AN XY:
24770
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000493 AC: 61AN: 1236972Hom.: 1 Cov.: 32 AF XY: 0.0000553 AC XY: 33AN XY: 597166
GnomAD4 exome
AF:
AC:
61
AN:
1236972
Hom.:
Cov.:
32
AF XY:
AC XY:
33
AN XY:
597166
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000223 AC: 34AN: 152280Hom.: 0 Cov.: 33 AF XY: 0.000201 AC XY: 15AN XY: 74462
GnomAD4 genome
AF:
AC:
34
AN:
152280
Hom.:
Cov.:
33
AF XY:
AC XY:
15
AN XY:
74462
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not specified Uncertain:1Benign:2
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Oct 24, 2017 | A variant of uncertain significance has been identified in the CACNA1A gene. The R2156L variant has not been published as a pathogenic variant, nor has it been reported as a benign variant to our knowledge. The R2156L variantis observed in 1/1162 (0.09%) alleles from individuals of Ashkenazi Jewish background and 3/12,428 (0.02%) alleles from individuals of African background, including 1 homozygous individual undergoing testing at GeneDx (Lek et al., 2016). The R2156L variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position where amino acids with similar properties to Arginine are tolerated across species. In silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic variant or a rare benignvariant. - |
Likely benign, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 08, 2024 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 20, 2021 | Variant summary: CACNA1A c.6467G>T (p.Arg2156Leu) results in a non-conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00022 in 150934 control chromosomes, predominantly at a frequency of 0.00058 (i.e. 24/41442 alleles) within the African or African-American subpopulation in the gnomAD v3.1 database. The number of occurrences is higher than expected for a pathogenic variant causing Early Infantile Epileptic Encephalopathy-42 (EE42), which tends to be a high penetrance, early onset disease (OMIM). To our knowledge, no occurrence of c.6467G>T in individuals affected with EE42 and no experimental evidence demonstrating its impact on protein function have been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014, and classified the variant as VUS (4x) or likely benign (1x). One of the ClinVar submitters cited evidence of lack of segregation with disease in a family study (SCV000848682.3) while another ClinVar submitter cited a homozygous occurrence of the variant in one individual undergoing testing (SCV000528812.3). Based on the evidence outlined above, the variant was classified as likely benign. - |
not provided Uncertain:2
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Aug 11, 2016 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Aug 01, 2019 | - - |
Episodic ataxia type 2;C4310716:Developmental and epileptic encephalopathy, 42 Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 08, 2024 | - - |
Inborn genetic diseases Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 28, 2021 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
CACNA1A-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 30, 2024 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
DEOGEN2
Uncertain
.;D;T;.;.;.;.;.;T;.;.;T;.;.;.;T;.;.
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;D;D;D;D;D;D;D;D;.;D;D;D;D;D;D;D
M_CAP
Pathogenic
D
MetaRNN
Benign
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Uncertain
.;.;.;.;M;.;.;.;.;.;.;.;.;.;.;.;.;.
PrimateAI
Uncertain
T
PROVEAN
Pathogenic
.;D;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.
REVEL
Benign
Sift
Uncertain
.;D;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.
Sift4G
Benign
T;T;.;.;.;D;.;.;.;.;.;.;.;.;.;.;.;.
Vest4
MVP
MPC
0.33
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at